Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TCRX TScan Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: TCRX
Price (delayed)
$1.38
Market cap
$78.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.09
Enterprise value
$15.99M
Highlights
TScan Therapeutics's quick ratio has surged by 62% YoY and by 4.9% QoQ
The EPS has increased by 8% YoY and by 4.4% QoQ
The equity has soared by 71% YoY but it has contracted by 13% from the previous quarter
TScan Therapeutics's revenue has shrunk by 70% YoY but it has surged by 57% QoQ
The company's net income fell by 36% YoY and by 3.1% QoQ
TScan Therapeutics's debt has increased by 6% YoY
Key stats
What are the main financial stats of TCRX
Market
Valuations
Earnings
Shares outstanding
56.59M
Market cap
$78.1M
Enterprise value
$15.99M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.37
Price to sales (P/S)
40.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.62
Revenue
$4.42M
Gross profit
$4.42M
Operating income
-$139.7M
Net income
-$131.48M
EBIT
-$128.11M
EBITDA
-$124.58M
Free cash flow
-$123.79M
Per share
Balance sheet
Liquidity
EPS
-$1.09
EPS diluted
-$1.09
Free cash flow per share
-$0.95
Book value per share
$3.71
Revenue per share
$0.03
TBVPS
$2.57
Total assets
$332.71M
Total liabilities
$122.51M
Debt
$97.04M
Equity
$210.2M
Working capital
$225.02M
Debt to equity
0.46
Current ratio
8.55
Quick ratio
8.61
Net debt/EBITDA
0.5
Margins
Efficiency
Dividend
EBITDA margin
-2,817.9%
Gross margin
100%
Net margin
-2,974.1%
Operating margin
-3,159.9%
Return on assets
-36.9%
Return on equity
-56.2%
Return on invested capital
-54.4%
Return on capital employed
-42.3%
Return on sales
-2,897.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TCRX stock price
How has the TScan Therapeutics stock price performed over time
Intraday
1.47%
1 week
-10.97%
1 month
16.95%
1 year
-82.77%
YTD
-54.61%
QTD
0%
Financial performance
How have TScan Therapeutics's revenue and profit performed over time
Revenue
$4.42M
Gross profit
$4.42M
Operating income
-$139.7M
Net income
-$131.48M
Gross margin
100%
Net margin
-2,974.1%
TScan Therapeutics's revenue has shrunk by 70% YoY but it has surged by 57% QoQ
TCRX's gross profit has plunged by 70% YoY but it has soared by 57% from the previous quarter
The company's operating income fell by 37% YoY and by 3.6% QoQ
The company's net income fell by 36% YoY and by 3.1% QoQ
Price vs fundamentals
How does TCRX's price correlate with its fundamentals
Growth
What is TScan Therapeutics's growth rate over time
Valuation
What is TScan Therapeutics stock price valuation
P/E
N/A
P/B
0.37
P/S
40.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.62
The EPS has increased by 8% YoY and by 4.4% QoQ
The equity has soared by 71% YoY but it has contracted by 13% from the previous quarter
The price to book (P/B) is 59% lower than the last 4 quarters average of 0.9
TScan Therapeutics's revenue has shrunk by 70% YoY but it has surged by 57% QoQ
The price to sales (P/S) is 42% lower than the last 4 quarters average of 69.7
Efficiency
How efficient is TScan Therapeutics business performance
The ROS has increased by 34% QoQ
TScan Therapeutics's ROE has increased by 8% YoY and by 6% from the previous quarter
The company's return on assets fell by 7% YoY but it rose by 3.4% QoQ
TScan Therapeutics's ROIC has increased by 6% from the previous quarter
Dividends
What is TCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TCRX.
Financial health
How did TScan Therapeutics financials performed over time
The total assets is 172% greater than the total liabilities
TCRX's current ratio has surged by 63% year-on-year and by 5% since the previous quarter
TScan Therapeutics's quick ratio has surged by 62% YoY and by 4.9% QoQ
TScan Therapeutics's debt is 54% lower than its equity
The equity has soared by 71% YoY but it has contracted by 13% from the previous quarter
The debt to equity has declined by 39% year-on-year but it has increased by 15% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.